PRECIGEN, INC. Increase (Decrease) in Contract with Customer, Liability
PRECIGEN, INC. (PGEN) reported Increase (Decrease) in Contract with Customer, Liability of -$233.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2026-08-04
- PRECIGEN, INC. increase (decrease) in contract with customer, liability for the quarter ending 2026-06-30 was -$126.00K.
- PRECIGEN, INC. increase (decrease) in contract with customer, liability for the quarter ending 2026-03-31 was -$107.00K.
- PRECIGEN, INC. increase (decrease) in contract with customer, liability for the quarter ending 2025-12-31 was -$58.00K, a 169.05% decline year-over-year.
- PRECIGEN, INC. increase (decrease) in contract with customer, liability for the quarter ending 2025-09-30 was -$1.66M, a 781.89% decline year-over-year.
- PRECIGEN, INC. increase (decrease) in contract with customer, liability for fiscal 2025 was -$2.01M, a 1123.47% decline from fiscal 2024.
- PRECIGEN, INC. increase (decrease) in contract with customer, liability for fiscal 2024 was $196.00K, a 59.50% decline from fiscal 2023.
- PRECIGEN, INC. increase (decrease) in contract with customer, liability for fiscal 2023 was $484.00K.
- PRECIGEN, INC. increase (decrease) in contract with customer, liability for fiscal 2022 was -$23.40M, a 1512.80% decline from fiscal 2021.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$126.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$233.00K 10-Q · filed 2026-08-04 | -$291.00K derived: sum of 3 quarters · filed 2026-08-04 | -$1.95M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | -$107.00K 10-Q · filed 2026-05-13 | -$165.00K derived: sum of 2 quarters · filed 2026-05-13 | -$1.82M derived: sum of 3 quarters · filed 2026-05-13 | -$1.98M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | -$58.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | -$1.72M derived: sum of 2 quarters · filed 2026-03-25 | -$1.87M derived: sum of 3 quarters · filed 2026-08-04 | -$2.01M 10-K · filed 2026-03-25 |
| 2025-09-30 | -$1.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$1.81M derived: sum of 2 quarters · filed 2026-08-04 | -$1.95M 10-Q · filed 2025-11-13 | -$1.86M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | -$153.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$291.00K 10-Q · filed 2026-08-04 | -$207.00K derived: sum of 3 quarters · filed 2026-08-04 | $36.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | -$138.00K 10-Q · filed 2026-05-13 | -$54.00K derived: sum of 2 quarters · filed 2026-05-13 | $189.00K derived: sum of 3 quarters · filed 2026-05-13 | $90.00K derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $84.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $327.00K derived: sum of 2 quarters · filed 2026-03-25 | $228.00K derived: sum of 3 quarters · filed 2026-03-25 | $196.00K 10-K · filed 2026-03-25 |
| 2024-09-30 | $243.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $144.00K derived: sum of 2 quarters · filed 2025-11-13 | $112.00K 10-Q · filed 2025-11-13 | $112.00K derived: sum of 4 quarters · filed 2026-03-25 |
| 2024-06-30 | -$99.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$131.00K 10-Q · filed 2025-08-12 | -$131.00K derived: sum of 3 quarters · filed 2026-03-25 | $363.00K derived: sum of 4 quarters · filed 2026-03-25 |
| 2024-03-31 | -$32.00K 10-Q · filed 2025-05-14 | -$32.00K derived: sum of 2 quarters · filed 2026-03-25 | $462.00K derived: sum of 3 quarters · filed 2026-03-25 | $430.00K derived: sum of 4 quarters · filed 2026-03-25 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $494.00K derived: sum of 2 quarters · filed 2026-03-25 | $462.00K derived: sum of 3 quarters · filed 2026-03-25 | $484.00K 10-K · filed 2026-03-25 |
| 2023-09-30 | $494.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $462.00K derived: sum of 2 quarters · filed 2024-11-14 | $484.00K 10-Q · filed 2024-11-14 | $431.00K derived: sum of 4 quarters · filed 2025-03-19 |
| 2023-06-30 | -$32.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$10.00K 10-Q · filed 2024-08-14 | -$63.00K derived: sum of 3 quarters · filed 2025-03-19 | -$21.22M derived: sum of 4 quarters · filed 2025-03-19 |
| 2023-03-31 | $22.00K 10-Q · filed 2024-05-14 | -$31.00K derived: sum of 2 quarters · filed 2025-03-19 | -$21.19M derived: sum of 3 quarters · filed 2025-03-19 | -$21.61M derived: sum of 4 quarters · filed 2025-03-19 |
| 2022-12-31 | -$53.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | -$21.21M derived: sum of 2 quarters · filed 2025-03-19 | -$21.63M derived: sum of 3 quarters · filed 2025-03-19 | -$23.40M 10-K · filed 2025-03-19 |
| 2022-09-30 | -$21.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$21.58M derived: sum of 2 quarters · filed 2023-11-09 | -$23.34M 10-Q · filed 2023-11-09 | -$22.59M derived: sum of 4 quarters · filed 2024-03-19 |
| 2022-06-30 | -$417.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$2.18M 10-Q · filed 2023-08-09 | -$1.43M derived: sum of 3 quarters · filed 2024-03-19 | -$1.01M derived: sum of 4 quarters · filed 2024-03-19 |
| 2022-03-31 | -$1.77M 10-Q · filed 2023-05-10 | -$1.01M derived: sum of 2 quarters · filed 2024-03-19 | -$593.00K derived: sum of 3 quarters · filed 2024-03-19 | -$1.17M derived: sum of 4 quarters · filed 2024-03-19 |
| 2021-12-31 | $753.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $1.17M derived: sum of 2 quarters · filed 2024-03-19 | $602.00K derived: sum of 3 quarters · filed 2024-03-19 | $1.66M 10-K · filed 2024-03-19 |
| 2021-09-30 | $421.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$151.00K derived: sum of 2 quarters · filed 2022-11-09 | $903.00K 10-Q · filed 2022-11-09 | $162.00K derived: sum of 4 quarters · filed 2023-03-06 |
| 2021-06-30 | -$572.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $482.00K 10-Q · filed 2022-08-08 | -$259.00K derived: sum of 3 quarters · filed 2023-03-06 | -$5.56M derived: sum of 4 quarters · filed 2023-03-06 |
| 2021-03-31 | $1.05M 10-Q · filed 2022-05-09 | $313.00K derived: sum of 2 quarters · filed 2023-03-06 | -$4.98M derived: sum of 3 quarters · filed 2023-03-06 | -$9.55M derived: sum of 4 quarters · filed 2023-03-06 |
| 2020-12-31 | -$741.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | -$6.04M derived: sum of 2 quarters · filed 2023-03-06 | -$10.61M derived: sum of 3 quarters · filed 2023-03-06 | -$21.05M 10-K · filed 2023-03-06 |
| 2020-09-30 | -$5.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | -$9.87M derived: sum of 2 quarters · filed 2021-11-08 | -$20.30M 10-Q · filed 2021-11-08 | -$17.94M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | -$4.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | -$15.01M 10-Q · filed 2021-08-09 | -$12.64M derived: sum of 3 quarters · filed 2022-03-01 | -$16.47M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | -$10.44M 10-Q · filed 2021-05-10 | -$8.07M derived: sum of 2 quarters · filed 2022-03-01 | -$11.90M derived: sum of 3 quarters · filed 2022-03-01 | -$4.34M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $2.37M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$1.47M derived: sum of 2 quarters · filed 2022-03-01 | $6.09M derived: sum of 3 quarters · filed 2022-03-01 | $7.42M 10-K · filed 2022-03-01 |
| 2019-09-30 | -$3.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $3.73M derived: sum of 2 quarters · filed 2020-11-09 | $5.06M 10-Q · filed 2020-11-09 | -$10.53M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $7.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $8.89M 10-Q · filed 2020-08-10 | -$6.70M derived: sum of 3 quarters · filed 2021-03-01 | -$14.04M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $1.33M 10-Q · filed 2020-05-11 | -$14.26M derived: sum of 2 quarters · filed 2021-03-01 | -$21.60M derived: sum of 3 quarters · filed 2021-03-01 | -$27.63M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | -$15.59M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | -$22.93M derived: sum of 2 quarters · filed 2021-03-01 | -$28.95M derived: sum of 3 quarters · filed 2021-03-01 | -$38.58M 10-K · filed 2021-03-01 |
| 2018-09-30 | -$7.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | -$13.37M derived: sum of 2 quarters · filed 2019-11-12 | -$22.99M 10-Q · filed 2019-11-12 | -$63.05M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | -$6.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | -$15.65M 10-Q · filed 2019-08-09 | -$55.70M derived: sum of 3 quarters · filed 2020-03-02 | |
| 2018-03-31 | -$9.62M 10-Q · filed 2019-05-09 | -$49.68M derived: sum of 2 quarters · filed 2020-03-02 | ||
| 2017-12-31 | -$40.06M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | -$75.34M 10-K · filed 2020-03-02 | ||
| 2017-09-30 | -$35.28M 10-Q · filed 2018-11-08 | |||
| 2016-12-31 | -$25.48M 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |